Axovant Sciences (AXON) Cut to “Market Perform” at Cowen
A number of other equities analysts also recently commented on the company. BidaskClub downgraded Axovant Sciences from a sell rating to a strong sell rating in a report on Friday, September 15th. Zacks Investment Research upgraded Axovant Sciences from a hold rating to a strong-buy rating and set a $8.00 price objective on the stock in a report on Monday, October 9th. HC Wainwright restated a buy rating on shares of Axovant Sciences in a report on Thursday, October 19th. Chardan Capital restated a sell rating and issued a $3.00 price objective on shares of Axovant Sciences in a report on Saturday, September 23rd. Finally, Oppenheimer restated a buy rating and issued a $30.00 price objective on shares of Axovant Sciences in a report on Monday, September 25th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $14.14.
Axovant Sciences (NASDAQ:AXON) opened at $2.09 on Friday. The firm has a market capitalization of $225.11, a PE ratio of -0.91 and a beta of 0.06. Axovant Sciences has a twelve month low of $2.06 and a twelve month high of $27.98. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34.
A number of institutional investors have recently made changes to their positions in AXON. FMR LLC boosted its position in Axovant Sciences by 968.5% during the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after purchasing an additional 6,558,462 shares during the period. Janus Henderson Group PLC bought a new stake in Axovant Sciences during the second quarter worth approximately $47,854,000. OxFORD Asset Management LLP boosted its position in Axovant Sciences by 842.1% during the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock worth $5,838,000 after purchasing an additional 777,505 shares during the period. Capital Research Global Investors boosted its position in Axovant Sciences by 21.8% during the second quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock worth $80,094,000 after purchasing an additional 619,226 shares during the period. Finally, Eagle Asset Management Inc. bought a new stake in Axovant Sciences during the third quarter worth approximately $4,471,000. 96.93% of the stock is owned by hedge funds and other institutional investors.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.